Clinical Assessment of a Closed-loop Insulin Delivery System
NCT ID: NCT01534013
Last Updated: 2020-10-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
23 participants
INTERVENTIONAL
2011-08-31
2018-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Type 1 diabetes is caused by antibodies attacking insulin-producing β-cells in the pancreas. Treatment is usually by regular insulin injections, informed by glucose measurements from fingerprick blood samples. However, injections do not mimic the normal behaviour of the β-cell and this leads to suboptimal blood glucose control and complications including kidney failure, blindness, nerve damage and heart disease. Aggressive treatment can help but may lead to potentially-dangerous low blood glucose levels (hypoglycaemia). Glucose control is measured by HbA1c (normal range 4 to 6%), a measure of the amount of haemoglobin exposed to glucose over a period of around 3 months.
Current regimens for treating Type 1 diabetes in clinical practice are mainly based on injections of subcutaneous insulin several times daily in dosages determined by intermittent blood glucose measurements. The DCCT (Diabetes Control and Complications Trial) demonstrated that intensive management using these principles reduced complications by 50-76%. This was at the expense of increased hypoglycaemia, especially at HbA1c levels \<7.5%. In other studies, intensive management resulted in people spending 30% of the day with glucose values \>10mM and \>2 hours/day in hypoglycaemia, often at night.
A closed loop system provides the potential to improve HbA1c while avoiding hypoglycaemia. It requires continuous glucose measurement, a control device and a pump for insulin delivery. The subject has been extensively reviewed. Intelligent control devices have been developed by others, using the principles of feedback control or predictive modelling. These were initially cumbersome e.g. the 'biostator' but more recent systems have been miniaturised and are capable of achieving blood glucose control in the fasting state, when provided with an input of interstitial glucose levels. They have not yet proven robust, may be associated with hypoglycaemia and are not capable of achieving adequate post-prandial control nor of coping with intercurrent illness outside hospital environments.
This clinical trial protocol assesses the Imperial College closed loop insulin delivery system. The closed loop insulin delivery comprises 3 main components: the glucose sensor, the control algorithm and the insulin delivery system.
The glucose sensor that will be used throughout the clinical validation studies is a CE marked, MHRA approved device manufactured by Medtronic. It is a subcutaneous sensor which sits just under the skin and samples interstitial fluid using an enzyme electrode. A small voltage is applied across the sensor and a current is fed back to the sensor instrumentation. This current is proportional to the glucose concentration in interstitial fluid and is calibrated against blood glucose a minimum of 12 hourly.
The control algorithm is derived from physiological experiments carried out by other groups which have demonstrated how the beta cells in the pancreas produce insulin in people without diabetes. Utilising the data from these experiments it has been possible to implement the behaviour of the beta cell in software and we have used a simulator with 200 virtual patients to demonstrate the safety and efficacy of the software. The data from the simulator is attached to this application as an appendix. The simulator was developed from human data and takes into account sensor errors, sensor placement, route of insulin administration and meal-time glucose absorption. It has been approved by the FDA in the United States as a step in the pathway of developing an artificial pancreas and has been validated against human data. In the clinical validation device the control algorithm is implemented on a printed circuit board using a programmable micro-controller.
The insulin pump device used throughout the clinical validation is the Roche Accu-Check Combo Spirit. This is a CE marked MHRA approved device and will be supplied by Roche with capability for direct communication from the motor so that we can verify the pump is doing what the software commands and with a license to use the communications protocol for research purposes. This ensures safe communication between the control algorithm and the pump and provides a fail-safe to ensure that the pump motor is responding appropriately to the control algorithm.
Clinical validation of the closed loop insulin delivery device follows a path of incremental challenges to the algorithm and hardware, starting with a fasting basal study in advisory mode and progressing to ambulatory, meal studies in full closed loop.
The aim of this trial is to assess the safety and efficacy of the closed loop device by applying the technology to participants with type 1 diabetes in a variety of scenarios, starting with a fasting test and progressing to overnight control, mealtime control and, finally, an ambulatory test.
Brief outline of each of the 5 visits within the trial period:
* Visit 1: Screening including clinical examination, fasting blood tests, completion of diabetes quality of life questionnaire, continuous glucose monitor attached to subject
* Visit 2: Review of continuous glucose monitoring results after 5 days
* Visit 3: Short Duration Fasting Closed Loop (6 hours of closed-loop assessment)
* Visit 4: Long Duration/ Overnight Fasting Closed Loop and Standard Meal Challenge (13 hours of closed-loop assessment)
* Visit 5: 24 Hour Ambulatory Automatic Closed Loop
During visits 3-5 blood sampling for capillary glucose \& ketones, venous glucose and insulin levels will take place every 15-30 minutes while the closed-loop insulin delivery system is running.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Closed-loop insulin delivery
The closed loop device (bio-inspired artificial pancreas device, subcutaneous glucose monitor and insulin pump) will be applied to participants with type 1 diabetes
The Imperial College Closed-Loop Insulin Delivery System
The Imperial College closed-loop insulin delivery system comprises 3 main components: the glucose sensor, the control algorithm and the insulin delivery system.
Open-loop (Control visit)
Subcutaneous glucose monitor and pump will be applied to participants with type 1 diabetes
Open loop
glucose sensor and pump
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The Imperial College Closed-Loop Insulin Delivery System
The Imperial College closed-loop insulin delivery system comprises 3 main components: the glucose sensor, the control algorithm and the insulin delivery system.
Open loop
glucose sensor and pump
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Type 1 diabetes confirmed on the basis of clinical features and a fasting c-peptide \<200nmol/L
* Type 1 diabetes for greater than 1 year
* Continuous subcutaneous insulin infusion for greater than 6 months
* HbA1c \< 8.5% (69mmol/mol)
Exclusion Criteria
* Pregnant or planning pregnancy
* Breastfeeding
* Enrolled in other clinical trials
* Have active malignancy or under investigation for malignancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imperial College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Desmond Johnston, MBChB,PhD,FRCP
Role: PRINCIPAL_INVESTIGATOR
Imperial College London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Imperial College London, St Mary's Campus
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Georgiou P, Toumazou C. A silicon pancreatic Beta cell for diabetes. IEEE Trans Biomed Circuits Syst. 2007 Mar;1(1):39-49. doi: 10.1109/TBCAS.2007.893178.
Georgiou P, Toumazou C. Towards an ultra low power chemically inspired electronic beta cell for diabetes. Circuits and Systems, 2006. ISCAS 2006. Proceedings. 2006 IEEE International Symposium on, p. 173, 2006.
Ho M, Georgiou P, Singhal S, Oliver NS, Toumazou C. A bio-inspired closed loop insulin delivery based on the silicon pancreatic beta-cell. Circuits and Systems, 2008. ISCAS 2008. IEEE International Symposium on, pp. 1052-1055, 2008
Oliver N, Georgiou P, Johnston D, Toumazou C. A benchtop closed-loop system controlled by a bio-inspired silicon implementation of the pancreatic beta cell. J Diabetes Sci Technol. 2009 Nov 1;3(6):1419-24. doi: 10.1177/193229680900300623.
Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med. 2006 Jan;23(1):1-12. doi: 10.1111/j.1464-5491.2005.01672.x.
Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T, Raskin R, Zinman B. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes,
Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W. An artificial endocrine pancreas. Diabetes. 1974 May;23(5):389-96. doi: 10.2337/diab.23.5.389. No abstract available.
Schaller HC, Schaupp L, Bodenlenz M, Wilinska ME, Chassin LJ, Wach P, Vering T, Hovorka R, Pieber TR. On-line adaptive algorithm with glucose prediction capacity for subcutaneous closed loop control of glucose: evaluation under fasting conditions in patients with Type 1 diabetes. Diabet Med. 2006 Jan;23(1):90-3. doi: 10.1111/j.1464-5491.2006.01695.x.
Kovatchev BP, Breton M, Man CD, Cobelli C. In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol. 2009 Jan;3(1):44-55. doi: 10.1177/193229680900300106.
Thome-Duret V, Reach G, Gangnerau MN, Lemonnier F, Klein JC, Zhang Y, Hu Y, Wilson GS. Use of a subcutaneous glucose sensor to detect decreases in glucose concentration prior to observation in blood. Anal Chem. 1996 Nov 1;68(21):3822-6. doi: 10.1021/ac960069i.
Reddy M, Herrero P, El Sharkawy M, Pesl P, Jugnee N, Thomson H, Pavitt D, Toumazou C, Johnston D, Georgiou P, Oliver N. Feasibility study of a bio-inspired artificial pancreas in adults with type 1 diabetes. Diabetes Technol Ther. 2014 Sep;16(9):550-7. doi: 10.1089/dia.2014.0009. Epub 2014 May 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13SM0363
Identifier Type: -
Identifier Source: org_study_id